

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
CS-2032 ZOSTER VACCINE OBTAINS CLINICAL TRIAL APPROVAL
FROM CANADA

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that, the Recombinant Zoster Vaccine (Adenovirus Vector) (the “**CS-2032 Zoster Vaccine**”) developed by the Group in co-operation with Vaccitech Limited has received a No Objection Letter for clinical trials from Health Canada.

The CS-2032 Zoster Vaccine adopts ChAdOx1 Vector technology route. The Adenovirus Vector vaccine is capable of triggering cellular immunity and humoral immunity simultaneously, and the vaccine candidate also adopts internationally leading process technology and a quality management and control system that meets international standards. During the entire production process of the vaccine candidate, no animal derived ingredients are used to improve the safety of the final product.

Both intramuscular injection version and aerosol inhalation version of CS-2032 Zoster Vaccine are approved for clinical trials. As showed in pre-clinical research data, the vaccine candidate was able to stimulate both humoral and cellular immunity, with no significant difference in humoral immunity compared to Shingrix, and can elicit significantly higher systemic cellular response than Shingrix. It is expected that the vaccine candidate has the potential to be a product with high efficacy profile. A clinical phase I trial of intramuscular injection and inhalation will be conducted simultaneously overseas to evaluate the safety and preliminary immunogenicity of the product.

The Company cannot guarantee that it will be able to develop, or ultimately commercialize CS-2032 Zoster Vaccine successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, July 23, 2023

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.